From messengers to receptors in psoriasis : The role of il-17ra in disease and treatment
Vidal, Silvia (Institut d'Investigació Biomèdica Sant Pau)
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
González-Cantero, Á. (Psoriasis and Inflammatory Skin Diseases Unit. Grupo Pedro Jaen)
Ruiz-Carrascosa, J.C. (Hospital Universitario San Cecilio (Granada))
Velasco-Pastor, A.M. (Hospital Arnau de Vilanova (València))

Date:	2021
Abstract:	The paradigm of psoriasis as a Th17-driven disease has evolved in the last years towards a much deeper knowledge of the complex pathways, mechanisms, cells, and messengers involved, highlighting the crucial role played by the IL-17 family of cytokines. All IL-17 isoforms signal through IL-17R. Five subunits of IL-17R have been described to date, which couple to form a homo-or heteroreceptor complex. Characteristically, IL-17RA is a common subunit in all hetero-receptors. IL-17RA has unique structural-containing a SEFIR/TILL domain-and functional-requiring ACT-1 for signaling-properties, enabling Th17 cells to act as a bridge between innate and adaptive immune cells. In psoriasis, IL-17RA plays a key role in pathogenesis based on: (a) IL-17A, IL-17F, and other IL-17 isoforms are involved in disease development; and (b) IL-17RA is essential for signaling of all IL-17 cytokines but IL-17D, whose receptor has not been identified to date. This article reviews current evidence on the biology and role of the IL-17 family of cytokines and receptors, with focus on IL-17RA, in psoriasis and some related comorbidities, and puts them in context with current and upcoming treatments.
Note:	Altres ajuts: Samsung-Bioepis, Amgen, Bristol-Myers Squibb (BMS), Pfizer, Novartis, Sanofi, Biogen, Celgene, AbbVie, Janssen Pharmaceuticals, UCB, Sandoz, Boehringer Ingelheim España, Roche España, LEO Pharma Research Foundation
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Subject:	Psoriasis ; Th17 ; IL-17 ; IL-17R ; Monoclonal antibodies ; Secukinumab ; Ixekizumab ; Bimekizumab ; Brodalumab
Published in:	International journal of molecular sciences, Vol. 22 Núm. 13 (january 2021) , p. 6740, ISSN 1422-0067

DOI: 10.3390/ijms22136740
PMID: 34201664

20 p, 724.5 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles